☰

Cecil T. Jordan, Ph.D. - Publications

Affiliations: 
2006 Pennsylvania State University, State College, PA, United States 
Area:
Writing
Tree Info Similar researchers PubMed Report error

0/276 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches (unlikely to be authored by this person)
2021 Penthala NR, Balasubramaniam M, Dachavaram SS, Morris EJ, Bhat-Nakshatri P, Ponder J, Jordan CT, Nakshatri H, Crooks PA. Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD). European Journal of Medicinal Chemistry. 224: 113675. PMID 34229108 DOI: 10.1016/j.ejmech.2021.113675  0.01
2021 Alwaseem H, Giovani S, Crotti M, Welle K, Jordan CT, Ghaemmaghami S, Fasan R. Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization. Acs Central Science. 7: 841-857. PMID 34079900 DOI: 10.1021/acscentsci.0c01624  0.01
2021 Chavez JS, Rabe JL, Loeffler D, Higa KC, Hernandez G, Mills TS, Ahmed N, Gessner RL, Ke Z, Idler BM, Niño KE, Kim H, Myers JR, Stevens BM, Davizon-Castillo P, Jordan CT, et al. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. The Journal of Experimental Medicine. 218. PMID 33857288 DOI: 10.1084/jem.20201169  0.01
2021 Jones CL, Inguva A, Jordan CT. Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. Cell Stem Cell. 28: 378-393. PMID 33667359 DOI: 10.1016/j.stem.2021.02.013  0.01
2021 Stevens BM, O'Brien C, Jordan CT, Jones CL. Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting. Star Protocols. 2: 100248. PMID 33437968 DOI: 10.1016/j.xpro.2020.100248  0.01
2021 Pollyea DA, Pei S, Stevens BM, Smith CA, Jordan CT. The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia Annual Review of Cancer Biology. 5: 277-289. DOI: 10.1146/annurev-cancerbio-060220-124048  0.01
2020 Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. Leukemia & Lymphoma. 1-9. PMID 33375853 DOI: 10.1080/10428194.2020.1864358  0.01
2020 Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 5. PMID 33268596 DOI: 10.1172/jci.insight.145847  0.01
2020 Pollyea DA, Kim HM, Stevens BM, Lee FF, Harris C, Hedin BR, Knapp JR, O'Connor BP, Jordan CT, Pietras EM, Tan AC, Alper S. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. Journal of Leukocyte Biology. PMID 33155727 DOI: 10.1002/JLB.6AB0520-318RR  0.01
2020 Walker ZJ, Idler B, Davis L, Stevens BM, VanWyngarden M, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-based Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33109736 DOI: 10.1158/1078-0432.CCR-20-2246  0.01
2020 Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, ... ... Jordan CT, et al. The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG. Cancer Discovery. PMID 33028621 DOI: 10.1158/2159-8290.CD-20-0318  0.01
2020 Fisher MH, Kirkpatrick GD, Stevens BM, Jones CL, Callaghan MU, Rajpurkar M, Fulbright J, Cooper MA, Rowley J, Porter CC, Gutierrez-Hartmann A, Jones K, Jordan CT, Pietras EM, Di Paola J. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. Jci Insight. PMID 32841218 DOI: 10.1172/Jci.Insight.140332  0.01
2020 Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, ... ... Jordan CT, et al. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. PMID 32822582 DOI: 10.1016/J.Stem.2020.07.021  0.01
2020 Yang C, Chen F, Ren P, Lofchy L, Wan C, Shen J, Wang G, Gaikwad H, Ponder J, Jordan CT, Scheinman R, Simberg D. Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32682903 DOI: 10.1016/J.Jconrel.2020.07.019  0.01
2020 Matheson CJ, Casalvieri KA, Backos DS, Minhajuddin M, Jordan CT, Reigan P. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. European Journal of Medicinal Chemistry. 197: 112316. PMID 32334266 DOI: 10.1016/J.Ejmech.2020.112316  0.01
2020 Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Advances. 4: 1628-1639. PMID 32311014 DOI: 10.1182/Bloodadvances.2019000122  0.01
2020 Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, ... ... Jordan CT, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery. PMID 31974170 DOI: 10.1158/2159-8290.Cd-19-0710  0.01
2020 Kent A, Pollyea DA, Winters A, Jordan CT, Smith C, Gutman JA. Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse Blood. 136: 11-12. DOI: 10.1182/blood-2020-138832  0.01
2020 Pollyea DA, Winters A, Jordan CT, Smith C, Gutman JA. Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy Blood. 136: 24-24. DOI: 10.1182/BLOOD-2020-138821  0.01
2020 Gutman JA, Winters A, Amaya ML, McMahon CM, Schowinsky J, Abbott D, Hammes A, Pei S, Stevens BM, Jordan CT, Smith C, Pollyea DA. Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features Blood. 136: 9-9. DOI: 10.1182/blood-2020-136120  0.01
2020 Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D’Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, ... Jordan CT, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells Nature Cancer. 1: 1176-1187. DOI: 10.1038/s43018-020-00126-z  0.01
2020 Inguva A, Pei S, Amaya M, Stevens B, Jones C, Pollyea D, Jordan C. 4353 The Role of BCL2 Mediated Calcium Signaling on Leukemia Stem Cell Metabolism Journal of Clinical and Translational Science. 4: 19-19. DOI: 10.1017/cts.2020.98  0.01
2020 Chavez J, Rabe J, Higa K, Loeffler D, Ahmed N, Mills T, Gessner R, Ke Z, Idler B, Stevens B, Fleenor C, Nakajima H, Hagman J, Kim H, Jordan C, et al. 3061 – PU.1 ENFORCES QUIESCENCE AND LIMITS HEMATOPOIETIC STEM CELL EXPANSION DURING CHRONIC INFLAMMATION Experimental Hematology. 88: S57. DOI: 10.1016/J.EXPHEM.2020.09.078  0.01
2019 Jordan CT. Can we selectively target AML stem cells? Best Practice & Research. Clinical Haematology. 32: 101100. PMID 31779978 DOI: 10.1016/J.Beha.2019.101100  0.01
2019 Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, ... ... Jordan CT, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Advances. 3: 2911-2919. PMID 31648312 DOI: 10.1182/Bloodadvances.2019000243  0.01
2019 Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Experimental Hematology. PMID 31136781 DOI: 10.1016/J.Exphem.2019.05.002  0.01
2019 Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Meyers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, ... Jordan CT, et al. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. PMID 31101752 DOI: 10.3324/Haematol.2018.197210  0.01
2019 Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, Jordan CT. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. PMID 31101624 DOI: 10.1182/Blood.2019898114  0.01
2019 Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, ... Jordan CT, et al. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leukemia Research. 81: 43-49. PMID 31009835 DOI: 10.1016/J.Leukres.2019.04.005  0.01
2019 Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, ... ... Jordan CT, et al. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Reports. 27: 238-254.e6. PMID 30943405 DOI: 10.1016/J.Celrep.2019.03.009  0.01
2019 Gregory MA, Nemkov T, Park HJ, Zaberezhnvv V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting glutamine metabolism and redox state for leukemia therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30940653 DOI: 10.1158/1078-0432.Ccr-18-3223  0.01
2019 Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica. PMID 30846499 DOI: 10.3324/Haematol.2018.214155  0.01
2019 Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, ... Jordan CT, et al. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 35: 333-335. PMID 30753831 DOI: 10.1016/j.ccell.2019.01.013  0.01
2019 Pollyea DA, Jordan CT. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? Current Opinion in Hematology. 26: 71-76. PMID 30652974 DOI: 10.1097/Moh.0000000000000485  0.01
2019 Pei S, Pollyea DA, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, ... ... Jordan CT, et al. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy Blood. 134: 185-185. DOI: 10.1182/Blood-2019-131390  0.01
2019 Chavez J, Rabe JL, Higa K, Loeffler D, Nouraiz A, Mills T, Idler BM, Stevens BM, Fleenor C, Nerlov C, Nakajima H, Hagman J, Schroeder T, Kim HM, Jordan CT, et al. PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation Blood. 134: 822-822. DOI: 10.1182/Blood-2019-129300  0.01
2019 Kaner JD, Tavakkoli M, Toudic L, Stevens BM, Jordan CT, Taldone T, Chiosis G, Ritchie EK, Desai P, Samuel MB, Lee S, Roboz GJ, Guzman ML. PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71 Blood. 134: 3935-3935. DOI: 10.1182/Blood-2019-128276  0.01
2019 Amaya ML, Inguva A, Jones CL, Krug A, Pei S, Reigan P, Jordan CT. STAT3 Plays a Critical Role in Mitochondrial Function and Survival of Primary AML Cells Blood. 134: 1275-1275. DOI: 10.1182/Blood-2019-127669  0.01
2019 Jones CL, Stevens BM, Culp-Hill R, Dalessandro A, Krug A, Goosman M, Pei S, Pollyea DA, Jordan CT. Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine Blood. 134: 1272-1272. DOI: 10.1182/Blood-2019-125773  0.01
2019 Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema K, Macero D, Hirose A, Boggs C, Falco A, ... ... Jordan CT, et al. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy Blood. 134: 2638-2638. DOI: 10.1182/Blood-2019-122120  0.01
2019 Walker ZJ, Idler BM, VanWyngarden MJ, Stevens BM, Bearrows SC, Davis LN, Hammes A, Smith C, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples Blood. 134: 4404-4404. DOI: 10.1182/Blood-2019-121937  0.01
2019 Matheson CJ, Casalvieri KA, Backos DS, Jordan CT, Reigan P. Abstract C078: Substituted oxindoles as AMP-activated protein kinase (AMPK) inhibitors and their evaluation in models of leukemia Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C078  0.01
2019 VanWyngarden M, Walker Z, Su Y, Bearrows S, Stevens B, Forsberg P, Mark T, Smith C, Matsui W, Jordan C, Liu B, Sherbenou D. CD46 Antibody Drug Conjugate Impedes Myeloma Engraftment in Patient-Derived Xenografts Clinical Lymphoma Myeloma and Leukemia. 19: e151. DOI: 10.1016/J.Clml.2019.09.252  0.01
2018 Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, ... Jordan CT, et al. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 34: 724-740.e4. PMID 30423294 DOI: 10.1182/Blood-2018-99-111965  0.01
2018 Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, ... ... Jordan CT, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine. PMID 30420752 DOI: 10.1038/S41591-018-0233-1  0.01
2018 Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 3. PMID 30385715 DOI: 10.1172/Jci.Insight.97941  0.01
2018 Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, ... ... Jordan CT, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/S41586-018-0623-Z  0.01
2018 Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, ... ... Jordan CT, et al. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell. PMID 30270124 DOI: 10.1016/J.Ccell.2018.08.016  0.01
2018 Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature Communications. 9: 3694. PMID 30209285 DOI: 10.1038/S41467-018-05984-X  0.01
2018 Janganati V, Ponder J, Balasubramaniam M, Bhat-Nakshatri P, Bar EE, Nakshatri H, Jordan CT, Crooks PA. MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells. European Journal of Medicinal Chemistry. 157: 562-581. PMID 30121494 DOI: 10.1016/J.Ejmech.2018.08.010  0.01
2018 Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, ... ... Jordan CT, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. PMID 29910151 DOI: 10.1016/J.Stem.2018.05.021  0.01
2018 Mills T, Hernandez G, Rabe JL, Kuldanek S, Chavez J, Kirkpatrick G, Noetzli L, Jubair W, Zanche M, Myers JR, Stevens BM, Fleenor C, Adane B, Ashton JM, Jordan CT, et al. Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality Blood. 132: 2573-2573. DOI: 10.1182/Blood-2018-99-120272  0.01
2018 Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, Pollyea DA, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia Blood. 132: 909-909. DOI: 10.1182/Blood-2018-99-119806  0.01
2018 Ye H, Adane B, Khan N, Minhajuddin M, Stevens BM, Pollyea DA, Jordan CT. Subversion of Systemic Glucose Metabolism As a Mechanism to Support the Growth of Leukemia Cells Blood. 132: 908-908. DOI: 10.1182/BLOOD-2018-99-117064  0.01
2018 Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz J, Ye H, Khan N, Minhajuddin M, DeGregori J, Pollyea DA, Jordan CT. Cysteine and Cystine Depletion Targets Leukemia Stem Cells Blood. 132: 431-431. DOI: 10.1182/Blood-2018-99-113181  0.01
2018 Jones CL, Stevens BM, D'Alessandro A, Reisz J, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Reinhold D, Smith C, DeGregori J, Pollyea DA, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells Blood. 132: 1521-1521. DOI: 10.1182/blood-2018-99-111965  0.01
2018 Pollyea DA, Jones CL, Stevens BM, Pei S, D'Alessandro A, Culp-Hill R, Abbott D, Hammes A, Dugan J, Gutman JA, Purev E, Smith C, Jordan CT. Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1 Blood. 132: 432-432. DOI: 10.1182/Blood-2018-99-111507  0.01
2018 Walker ZJ, VanWyngarden MJ, Stevens BM, Langouët-Astrie C, Smith C, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients Blood. 132: 3203-3203. DOI: 10.1182/Blood-2018-99-111394  0.01
2018 Jones CL, Stevens BM, Culp-Hill R, Nemkov T, D'Alessandro A, Pei S, Pollyea DA, Jordan CT. Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism Blood. 132: 429-429. DOI: 10.1182/Blood-2018-99-111366  0.01
2018 Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant Blood. 132: 2138-2138. DOI: 10.1182/Blood-2018-99-110834  0.01
2017 Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC. A small molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Molecular Cancer Therapeutics. PMID 28655785 DOI: 10.1158/1535-7163.Mct-16-0660  0.01
2017 Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA. Succinamide derivatives of melampomagnolide B and their anti-cancer activities. Bioorganic & Medicinal Chemistry. PMID 28545815 DOI: 10.1016/J.Bmc.2017.05.008  0.01
2017 Bommagani S, Ponder J, Penthala NR, Janganati V, Jordan CT, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. European Journal of Medicinal Chemistry. 136: 393-405. PMID 28525840 DOI: 10.1016/J.Ejmech.2017.05.031  0.01
2017 Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica. PMID 28280079 DOI: 10.3324/Haematol.2016.159053  0.01
2017 Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 129: 1627-1635. PMID 28159738 DOI: 10.1182/Blood-2016-10-696039  0.01
2017 Mills T, Hernandez G, Kuldanek S, Rabe JL, Kirkpatrick G, Noetzli L, Severs E, Ir D, Acharya S, Adane B, Jordan CT, Paola JD, Frank D, Kuhn K, Holers M, et al. Altered HSC Programming Drives Aberrant Blood Output Underlying RA Pathogenesis Blood. 130: 3748-3748. DOI: 10.1182/Blood.V130.Suppl_1.3748.3748  0.01
2017 Zhang W, Stevens BM, Budde EE, Forman SJ, Jordan CT, Purev E. Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome Blood. 130: 1917-1917. DOI: 10.1182/Blood.V130.Suppl_1.1917.1917  0.01
2017 Pollyea DA, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies Blood. 130: 181-181. DOI: 10.1182/Blood.V130.Suppl_1.181.181  0.01
2017 Stevens BM, Winters A, Gutman JA, Fullerton A, Hemenway G, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky LM, Cogle CR, Hammes A, Jordan CT, Pollyea DA. Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics Blood. 130: 1337-1337. DOI: 10.1182/Blood.V130.Suppl_1.1337.1337  0.01
2017 Zahreddine H, Kraljacic-Culjkovic B, Cali V, Lauer M, Skrabanek L, Khan N, Midura R, Cerchietti L, Hascall V, Jordan C. Abstract 4898: eIF4E reshapes the surface of migrating AML cells through regulating Hyaluronic Acid synthesis & CD44 expression Cancer Research. 77: 4898-4898. DOI: 10.1158/1538-7445.Am2017-4898  0.01
2017 Pietras E, Hernandez G, Kuldanek S, Jennifer R, Kirkpatrick G, Noetzli L, Acharya S, Adane B, Jordan C, DiPaola J, Holers M, Banda N. Altered HSC fate underlies aberrant blood phenotypes in rheumatoid arthritis Experimental Hematology. 53: S71. DOI: 10.1016/J.Exphem.2017.06.143  0.01
2016 Albayati ZA, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Bioorganic & Medicinal Chemistry. PMID 28049618 DOI: 10.1016/J.Bmc.2016.12.036  0.01
2016 Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, ... ... Jordan CT, et al. Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells. The Journal of Biological Chemistry. 291: 25280. PMID 27888238 DOI: 10.1074/jbc.A116.750653  0.01
2016 Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 113: E6669-E6678. PMID 27791036 DOI: 10.1073/Pnas.1603876113  0.01
2016 Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorganic & Medicinal Chemistry. PMID 27687970 DOI: 10.1016/J.Bmc.2016.09.043  0.01
2016 Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, ... ... Jordan CT, et al. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. The Journal of Biological Chemistry. PMID 27573247 DOI: 10.1074/Jbc.M116.750653  0.01
2016 Gupta P, Jordan CT, Mitov MI, Butterfield DA, Hilt JZ, Dziubla TD. Controlled Curcumin Release via Conjugation into PBAE Nanogels Enhances Mitochondrial Protection against Oxidative Stress. International Journal of Pharmaceutics. PMID 27492022 DOI: 10.1016/J.Ijpharm.2016.07.071  0.01
2016 Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. Evolution of acute myelogenous leukemia stem cell properties following treatment and progression. Blood. PMID 27421961 DOI: 10.1182/Blood-2016-02-695312  0.01
2016 Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R. Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. Bioorganic & Medicinal Chemistry. PMID 27396927 DOI: 10.1016/J.Bmc.2016.06.028  0.01
2016 Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. PMID 27374788 DOI: 10.1016/J.Stem.2016.06.001  0.01
2016 Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Acute myeloid leukaemia. Nature Reviews. Disease Primers. 2: 16010. PMID 27159408 DOI: 10.1038/nrdp.2016.10  0.01
2016 Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. Jci Insight. 1: e85630. PMID 27158668 DOI: 10.1172/Jci.Insight.85630  0.01
2016 Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. The Journal of Clinical Investigation. PMID 26927674 DOI: 10.1172/Jci80825  0.01
2016 Højen JF, Taylor MK, Azam T, Fischer S, Pollyea DA, Jordan CT, Dinarello CA. Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation Blood. 128: 5224-5224. DOI: 10.1182/Blood.V128.22.5224.5224  0.01
2016 Stevens BM, Pollyea DA, Khan N, Jordan CT. Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention Blood. 128: 4316-4316. DOI: 10.1182/Blood.V128.22.4316.4316  0.01
2016 Page LS, Wang X, Earp HS, Frye S, Jordan CT, Lee-Sherick AB. MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia Blood. 128: 4044-4044. DOI: 10.1182/Blood.V128.22.4044.4044  0.01
2016 Ye H, Khan N, Minhajuddin M, Adane B, Jordan CT. Adipose Tissue-Derived IGFBP1 Facilitates Progression of Leukemia Blood. 128: 3058-3058. DOI: 10.1182/Blood.V128.22.3058.3058  0.01
2016 Nooruddin Z, Pan Z, Gross L, David W, Haverkos BM, Pollyea DA, Gutman JA, Robinson W, Smith C, Schowinsky J, Enkhtsetseg P, Sherbenou DW, Rabinovitch R, Ney D, Jordan CT, et al. Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes Blood. 128: 3054-3054. DOI: 10.1182/Blood.V128.22.3054.3054  0.01
2016 Jones CL, Kirkpatrick G, Fleenor C, Seth W, Noetzli LJ, Fosmire S, Baturin D, Liang X, Hernandez G, Pietras EM, Jordan CT, Rowley JW, Di Paola J, Hagman JR, Porter CC. ETV6 Regulates Pax5 Expression in Early B Cell Development Blood. 128: 2655-2655. DOI: 10.1182/Blood.V128.22.2655.2655  0.01
2016 Pei S, Minhajuddin M, Adane B, Stevens BM, Khan N, D'alessandro A, Nemkov T, Hansen KC, Pollyea DA, Jordan CT. Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia Blood. 128: 1703-1703. DOI: 10.1182/Blood.V128.22.1703.1703  0.01
2016 Adane B, Ye H, Pei S, Khan N, Minhajuddin M, Stevens BM, Zaberezhnyy V, Pollyea DA, Jordan CT. The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis Blood. 128: 1079-1079. DOI: 10.1182/Blood.V128.22.1079.1079  0.01
2016 Riedel S, Haladyna J, Stevens B, Pollyea D, Wei Q, Jordan C, Ernst P, Neff T, Bernt K. Abstract IA11: Meningioma-1 cooperates with MLL and DOT1L to induce leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Ia11  0.01
2015 Hyrien O, Yanev NM, Jordan CT. A test of homogeneity for age-dependent branching processes with immigration. Electronic Journal of Statistics. 9: 898-925. PMID 27134694 DOI: 10.1214/15-Ejs1024  0.01
2015 Smith KS, Yadav VK, Pei S, Pollyea DA, Jordan CT, De S. SomVarIUS: Somatic variant identification from unpaired tissue samples. Bioinformatics (Oxford, England). PMID 26589277 DOI: 10.1093/Bioinformatics/Btv685  0.01
2015 Crooks PA, Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthala NR. Dimers of melampomagnolide B exhibit potent anticancer activity against hematological and solid tumor cells. Journal of Medicinal Chemistry. PMID 26540463 DOI: 10.1021/Acs.Jmedchem.5B01187  0.01
2015 Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leukemia & Lymphoma. 1-22. PMID 26389776 DOI: 10.3109/10428194.2015.1094697  0.01
2015 Ammar M, Jordan CT, Cao L, Lim E, Bouchlaka Souissi C, Jrad A, Omrane I, Kouidhi S, Zaraa I, Anbunathan H, Mokni M, Doss N, Guttman-Yassky E, El Gaaied B, Menter A, et al. CARD14 alterations in Tunisian psoriasis patients and further characterization in European cohorts. The British Journal of Dermatology. PMID 26358359 DOI: 10.1111/Bjd.14158  0.01
2015 Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, et al. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget. 6: 14796-813. PMID 26142707 DOI: 10.18632/Oncotarget.4193  0.01
2015 Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Research. 25: 707-25. PMID 25952668 DOI: 10.1038/Cr.2015.56  0.01
2015 Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 6: 6722-36. PMID 25762638 DOI: 10.18632/Oncotarget.3156  0.01
2015 Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1360-72. PMID 25547679 DOI: 10.1158/1078-0432.Ccr-14-2146  0.01
2015 Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. Advances in Experimental Medicine and Biology. 815: 349-59. PMID 25427917 DOI: 10.1007/978-3-319-09614-8_20  0.01
2015 Hyrien O, Yanev NM, Jordan CT. A test of homogeneity for age-dependent branching processes with immigration Electronic Journal of Statistics. 9: 898-925. DOI: 10.1214/15-EJS1024  0.01
2015 Ye H, Adane B, Khan N, Ashton JM, Balys M, Stevens BM, Minhajuddin M, Jordan CT. Adipose Tissue Functions As a Reservoir for Leukemia Stem Cells and Confers Chemo-Resistance Blood. 126: 845-845. DOI: 10.1182/Blood.V126.23.845.845  0.01
2015 Pei S, Minhajuddin M, Stevens BM, Adane B, Khan N, D'alessandro A, Nemkov T, Hansen KC, Pollyea D, Jordan CT. Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function Blood. 126: 842-842. DOI: 10.1182/Blood.V126.23.842.842  0.01
2015 Seligman PA, Pei S, Parrish JR, Schleicher RB, Singal P, Jordan CT. Cellular Iron Status Is Associated with Better Survival and Increased Chemotherapy Sensitivity in AML Blood. 126: 4975-4975. DOI: 10.1182/Blood.V126.23.4975.4975  0.01
2015 Ho T, Jordan CT, LaMere MW, Ashton JM, O'Dwyer K, Mendler JH, Liesveld JL, Wang ES, Guzman ML, Calvi LM, Becker MW. A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression Blood. 126: 4266-4266. DOI: 10.1182/Blood.V126.23.4266.4266  0.01
2015 Stevens BM, Pollyea D, Khan N, Jordan CT. Characterization and Targeting of Myelodysplastic Syndrome Stem Cells Blood. 126: 4104-4104. DOI: 10.1182/Blood.V126.23.4104.4104  0.01
2015 Jeyaraju DV, Hurren R, Wang X, MacLean N, Gronda M, Jordan CT, Minden MD, Giaever G, Schimmer AD. A Novel Isoflavone, ME-344, Targets the Cytoskeleton in Acute Myeloid Leukemia Blood. 126: 3682-3682. DOI: 10.1182/Blood.V126.23.3682.3682  0.01
2015 Ye H, Khan N, Balys M, Ashton JM, Adane B, Jordan CT. Leukemia Cells Resident in Adipose Tissue Display a Pro-Inflammatory Phenotype and Induce Lipolysis and Atrophy of Adipose Tissue Blood. 126: 2765-2765. DOI: 10.1182/Blood.V126.23.2765.2765  0.01
2015 Riedel S, Haladyna J, Stevens B, Jordan CT, Pollyea D, Armstrong SA, Wei Q, Ernst P, Neff T, Bernt KM. Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia Blood. 126: 2428-2428. DOI: 10.1182/Blood.V126.23.2428.2428  0.01
2015 Nooruddin Z, Robinson W, Pollyea D, Gutman JA, Smith C, Pan Z, Jordan CT, Rabinovitch R, Schowinsky J, Lu X, Ney D, Kamdar M. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience Blood. 126: 1443-1443. DOI: 10.1182/Blood.V126.23.1443.1443  0.01
2015 Baranello MP, Bauer L, Jordan CT, Benoit DSW. Micelle Delivery of Parthenolide to Acute Myeloid Leukemia Cells Cellular and Molecular Bioengineering. 8: 455-470. DOI: 10.1007/s12195-015-0391-x  0.01
2014 Kim SW, Schifano M, Oleksyn D, Jordan CT, Ryan D, Insel R, Zhao J, Chen L. Protein kinase C-associated kinase regulates NF-κB activation through inducing IKK activation. International Journal of Oncology. 45: 1707-14. PMID 25096806 DOI: 10.3892/Ijo.2014.2578  0.01
2014 Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 99: 1277-84. PMID 25082785 DOI: 10.3324/Haematol.2013.085209  0.01
2014 Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular Cancer Therapeutics. 13: 1979-90. PMID 24934933 DOI: 10.1158/1535-7163.Mct-13-0963  0.01
2014 Gandhi UH, Kaushal N, Hegde S, Finch ER, Kudva AK, Kennett MJ, Jordan CT, Paulson RF, Prabhu KS. Selenium suppresses leukemia through the action of endogenous eicosanoids. Cancer Research. 74: 3890-901. PMID 24872387 DOI: 10.1158/0008-5472.CAN-13-3694  0.01
2014 Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511: 90-3. PMID 24870236 DOI: 10.1038/Nature13283  0.01
2014 Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. Annals of the New York Academy of Sciences. 1310: 58-68. PMID 24641679 DOI: 10.1111/Nyas.12414  0.01
2014 Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CT, et al. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 28: 1960-8. PMID 24577530 DOI: 10.1038/Leu.2014.93  0.01
2014 Liu S, Miriyala S, Keaton MA, Jordan CT, Wiedl C, Clair DK, Moscow JA. Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. Plos One. 9: e85702. PMID 24454921 DOI: 10.1371/Journal.Pone.0085702  0.01
2014 Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. The Journal of Clinical Investigation. 124: 222-36. PMID 24334453 DOI: 10.1172/Jci66005  0.01
2014 Kolev JN, O'Dwyer KM, Jordan CT, Fasan R. Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization. Acs Chemical Biology. 9: 164-73. PMID 24206617 DOI: 10.1021/Cb400626W  0.01
2014 Riedel S, Bernt KM, Haladyna J, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin Blood. 124: 838-838. DOI: 10.1182/Blood.V124.21.838.838  0.01
2014 Gasparetto M, Pei S, Minhajuddin M, Pollyea DA, Vasiliou V, Humphries RK, Jordan CT, Smith CA. Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance Blood. 124: 2238-2238. DOI: 10.1182/Blood.V124.21.2238.2238  0.01
2014 Velu CS, Chaubey A, Phelan JD, Meyer S, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, et al. Abstract 979: microRNA-mediated leukemia-initiating cell activity Cancer Research. 74: 979-979. DOI: 10.1158/1538-7445.Am2014-979  0.01
2013 Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leukemia Research. 37: 1622-7. PMID 24138944 DOI: 10.1016/J.Leukres.2013.09.002  0.01
2013 Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, ... Jordan CT, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. The Journal of Biological Chemistry. 288: 33542-58. PMID 24089526 DOI: 10.1074/Jbc.M113.511170  0.01
2013 Howard DS, Liesveld J, Phillips GL, Hayslip J, Weiss H, Jordan CT, Guzman ML. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leukemia Research. 37: 1502-8. PMID 24075534 DOI: 10.1016/J.Leukres.2013.09.003  0.01
2013 Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, ... Jordan CT, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 24: 45-58. PMID 23770013 DOI: 10.1016/J.Ccr.2013.05.004  0.01
2013 Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental Hematology. 41: 799-807.e4. PMID 23660068 DOI: 10.1016/J.Exphem.2013.04.012  0.01
2013 Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH, Mann KK. Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. Frontiers in Pharmacology. 4: 9. PMID 23408639 DOI: 10.3389/Fphar.2013.00009  0.01
2013 Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 12: 329-41. PMID 23333149 DOI: 10.1016/J.Stem.2012.12.013  0.01
2013 Ammar M, Bouchlaka-Souissi C, Helms CA, Zaraa I, Jordan CT, Anbunathan H, Bouhaha R, Kouidhi S, Doss N, Dhaoui R, Ben Osman A, Ben Ammar El Gaied A, Marrakchi R, Mokni M, Bowcock AM. Genome-wide linkage scan for psoriasis susceptibility loci in multiplex Tunisian families. The British Journal of Dermatology. 168: 583-7. PMID 23013406 DOI: 10.1111/Bjd.12050  0.01
2013 Sampson ER, McMurray HR, Hassane DC, Newman L, Salzman P, Jordan CT, Land H. Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene. 32: 3809-18. PMID 22964631 DOI: 10.1038/Onc.2012.389  0.01
2013 Gasparetto M, Jordan CT, Minhajuddin M, Pollyea DA, Vasilou V, Reigan P, Humphries RK, Smith CA. ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May Be Exploited to Treat AML Blood. 122: 2893-2893. DOI: 10.1182/Blood.V122.21.2893.2893  0.01
2012 Pei S, Jordan CT. How close are we to targeting the leukemia stem cell? Best Practice & Research. Clinical Haematology. 25: 415-8. PMID 23200537 DOI: 10.1016/J.Beha.2012.10.003  0.01
2012 Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, Ebert BL, McMurray HR, Land H, Jordan CT. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell. 11: 359-72. PMID 22863534 DOI: 10.1016/J.Stem.2012.05.024  0.01
2012 Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. American Journal of Human Genetics. 90: 796-808. PMID 22521419 DOI: 10.1016/J.Ajhg.2012.03.013  0.01
2012 Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, et al. PSORS2 is due to mutations in CARD14. American Journal of Human Genetics. 90: 784-95. PMID 22521418 DOI: 10.1016/J.Ajhg.2012.03.012  0.01
2012 Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, Jordan CT, Boyce BF. Noncanonical NF-κB signaling regulates hematopoietic stem cell self-renewal and microenvironment interactions. Stem Cells (Dayton, Ohio). 30: 709-18. PMID 22290873 DOI: 10.1182/Blood.V118.21.859.859  0.01
2012 Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 119: 540-50. PMID 21957195 DOI: 10.1182/Blood-2011-04-348151  0.01
2012 Liesveld JL, O'Dwyer K, Becker MW, Mulford D, Walker A, Chen R, Bechelli J, Rosell K, Jordan CT, Minhajuddin M, Phillips GL. Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia Blood. 120: 3549-3549. DOI: 10.1182/Blood.V120.21.3549.3549  0.01
2012 Lagadinou ED, Sach A, Callahan KP, Rossi RM, Neering S, Pei S, O'Dwyer K, Liesveld JL, Brookes PS, Becker MW, Jordan CT. Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells Blood. 120: 206-206. DOI: 10.1182/Blood.V120.21.206.206  0.01
2012 Callahan KP, Corbett C, Jacob S, Minhajuddin M, Lagadinou ED, Rossi RM, Gross V, Balys M, Hagen F, Frontier AJ, Jordan CT. Rocaglamide Selectively Eradicates Human Leukemia Stem Cells and Synergizes with Multiple Agents to Target AML Cells Blood. 120: 1338-1338. DOI: 10.1182/Blood.V120.21.1338.1338  0.01
2011 Becker MW, Jordan CT. Leukemia stemness signatures step toward the clinic. Cell Stem Cell. 9: 185-6. PMID 21885015 DOI: 10.1016/J.Stem.2011.08.006  0.01
2011 Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. Plos One. 6: e23108. PMID 21853076 DOI: 10.1371/Journal.Pone.0023108  0.01
2011 Nasim S, Guzman ML, Jordan CT, Crooks PA. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. Bioorganic & Medicinal Chemistry Letters. 21: 4879-83. PMID 21757349 DOI: 10.1016/J.Bmcl.2011.06.027  0.01
2011 Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Investigation. 29: 439-50. PMID 21740082 DOI: 10.3109/07357907.2011.590567  0.01
2011 Nasim S, Pei S, Hagen FK, Jordan CT, Crooks PA. Melampomagnolide B: a new antileukemic sesquiterpene. Bioorganic & Medicinal Chemistry. 19: 1515-9. PMID 21273084 DOI: 10.1016/J.Bmc.2010.12.045  0.01
2011 Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 591-9. PMID 21220598 DOI: 10.1200/Jco.2010.31.0904  0.01
2011 Becker MW, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. Blood Reviews. 25: 75-81. PMID 21216511 DOI: 10.1016/J.Blre.2010.11.001  0.01
2011 Brigham PMGS, Miller W, Al-Shahrour F, Hartwell KA, Chu LP, Marcus J, Puram RV, Puissant A, Callahan K, Ashton JM, McConkey ME, Poveromo L, Cowley G, Kharas MG, Labelle M, ... Jordan CT, et al. In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling Blood. 118: 758-758. DOI: 10.1182/Blood.V118.21.758.758  0.01
2011 Lagadinou E, Callahan K, Neering SJ, Pei S, Minhajuddin M, Rossi RM, Grose V, Corbett C, Balys M, Brookes P, Jordan CT. Reactive Oxygen Species (ROS) Levels Define Functional Heterogeneity in Human Leukemia Stem Cells and Represent a Critical Parameter for Therapeutic Targeting Blood. 118: 639-639. DOI: 10.1182/Blood.V118.21.639.639  0.01
2011 Ashton JM, Balys M, Neering S, Cowley G, Root DE, Miller PG, Ebert B, McMurray H, Hassane DC, Land H, Jordan CT. Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells Blood. 118: 553-553. DOI: 10.1182/Blood.V118.21.553.553  0.01
2011 Pei S, Callahan K, Minhajuddin M, Balys M, Neering S, Corbett C, Becker MW, Liesveld JL, Hagen F, Friedman AE, Crooks P, Jordan CT. Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells, Blood. 118: 3506-3506. DOI: 10.1182/Blood.V118.21.3506.3506  0.01
2011 Minhajuddin M, Pei S, Ashton JM, Callahan K, Lagadinou E, Balys M, Corbett C, Neering S, Rossi RM, Jordan CT. Molecular Mechanisms of Parthenolide-Mediated Pro-Apoptotic Activity in Acute Myeloid Leukemia Cells Blood. 118: 2463-2463. DOI: 10.1182/Blood.V118.21.2463.2463  0.01
2011 Hassane DC, Leon JPD, Corbett C, Rossi RM, Xie W, Jordan CT, Guzman ML. Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction Blood. 118: 1885-1885. DOI: 10.1182/Blood.V118.21.1885.1885  0.01
2011 Xie W, Hassane DC, Jordan CT, Roboz GJ, Guzman ML. High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin Blood. 118: 1430-1430. DOI: 10.1182/Blood.V118.21.1430.1430  0.01
2011 Yang N, Hassane DC, Balys M, Corbett CA, Jordan CT, Guzman ML. Abstract 2145: AR-42, a novel histone deacetylase inhibitor with selectivity against leukemia stem cell via apoptosis induction, inhibition of chaperone function of heat shock protein 90 in acute myeloid leukemia Cancer Research. 71: 2145-2145. DOI: 10.1158/1538-7445.Am2011-2145  0.01
2011 Benito J, Shi Y, Lu H, Konoplev S, Fang W, Kornblau S, Zweidler-McKay PA, Qiu Y, Wilson W, Campana D, Borthakur G, Bueso-Ramos C, Kantarjian H, Shpall E, Thomas DA, ... Jordan C, et al. 203 Hypoxic Leukemic Microenvironment and its Targeting by the Hypoxia-Activated Prodrug PR-104 Clinical Lymphoma Myeloma and Leukemia. 11: S124. DOI: 10.1016/J.Clml.2011.05.013  0.01
2010 Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 116: 5983-90. PMID 20889920 DOI: 10.1182/Blood-2010-04-278044  0.01
2010 Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology. 151: 70-83. PMID 20701602 DOI: 10.1111/J.1365-2141.2010.08319.X  0.01
2010 Silvers CR, Williams K, Salamone L, Huang J, Jordan CT, Zhou H, Palapattu GS. A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. The Prostate. 70: 1379-87. PMID 20687210 DOI: 10.1002/Pros.21171  0.01
2010 Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, ... Jordan CT, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 466: 765-8. PMID 20639863 DOI: 10.1038/Nature09171  0.01
2010 Jordan CT. Targeting myeloid leukemia stem cells. Science Translational Medicine. 2: 31ps21. PMID 20463365 DOI: 10.1126/Scitranslmed.3000914  0.01
2010 Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/J.Bbmt.2010.03.002  0.01
2010 Benito J, Shi Y, Szymanska B, Carol H, Bohem I, Lu H, Konoplev S, Fang W, Kornblau SM, Zweidler-McKay P, Wilson W, Campana D, Borthakur G, Bueso-Ramos CE, Kantarjian HM, ... ... Jordan CT, et al. Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104 Blood. 116: 868-868. DOI: 10.1182/Blood.V116.21.868.868  0.01
2010 Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Zeleznik-Le N, Jordan CT, Carroll M, Gebelein B, Grimes HL. Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance Blood. 116: 4192-4192. DOI: 10.1182/Blood.V116.21.4192.4192  0.01
2010 Lagadinou ED, Kokkinou D, Siapati E, Vassilopoulos G, Jordan CT, Spyridonidis A. Isolation and Functional Characterization of a Novel “Oxidative State – low” Leukemic Population with Stem Cell Properties and Potential Resistance to Chemotherapy In Acute Myeloid Leukemia. Blood. 116: 1580-1580. DOI: 10.1182/Blood.V116.21.1580.1580  0.01
2010 Frisch BJ, Ashton JM, Jordan CT, Calvi LM. Microenvironmental Changes In An In Vivo Model of Myeloid Leukemia Negatively Regulate Osteoblastic Cells. Blood. 116: 1219-1219. DOI: 10.1182/Blood.V116.21.1219.1219  0.01
2010 Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim S, Kim D, Chuah C, ... ... Jordan CT, et al. P73. Regulation of myeloid leukemia by the cell fate determinant Musashi Differentiation. 80: S41. DOI: 10.1016/J.Diff.2010.09.079  0.01
2009 Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, Jordan CT, Guzman ML, Maggirwar SB, Briehl MM, Bernstein SH. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. Plos One. 4: e8115. PMID 19956548 DOI: 10.1371/Journal.Pone.0008115  0.01
2009 Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, Calvi LM. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood. 114: 4054-63. PMID 19726721 DOI: 10.1182/Blood-2009-03-205823  0.01
2009 Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science (New York, N.Y.). 324: 1670-3. PMID 19556499 DOI: 10.1126/Science.1171837  0.01
2009 Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. International Journal of Radiation Oncology, Biology, Physics. 74: 1580-91. PMID 19540073 DOI: 10.1016/J.Ijrobp.2009.03.047  0.01
2009 Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorganic & Medicinal Chemistry Letters. 19: 4346-9. PMID 19505822 DOI: 10.1016/J.Bmcl.2009.05.092  0.01
2009 Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, et al. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia. 23: 1587-97. PMID 19440216 DOI: 10.1038/Leu.2009.99  0.01
2009 Guzman ML, Jordan CT. Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. Cancer Cell. 15: 252-4. PMID 19345324 DOI: 10.1016/J.Ccr.2009.03.008  0.01
2009 Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell. 4: 203-5. PMID 19265659 DOI: 10.1016/J.Stem.2009.02.003  0.01
2009 Jordan CT. Making Sense of Leukemia Stem Cells: Our Current Understanding and Future Directions. Blood. 114. DOI: 10.1182/Blood.V114.22.Sci-36.Sci-36  0.01
2009 Chaubey A, Velu CS, Horman S, Jegga A, Guzman ML, Risner L, Zeleznik-Le NJ, Jordan CT, Carroll M, Gebelein B, Grimes HL. Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation. Blood. 114: 3966-3966. DOI: 10.1182/Blood.V114.22.3966.3966  0.01
2009 Hassane D, Sen S, Corbett CA, Balys M, Rossi RM, Crooks PA, Guzman ML, Jordan CT. Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide. Blood. 114: 388-388. DOI: 10.1182/Blood.V114.22.388.388  0.01
2009 Skalska J, Brookes PS, Nadtochy SM, Hilchey S, Jordan CT, Guzman ML, Maggirwar S, Briehl MM, Bernstein SH. Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma. Blood. 114: 3774-3774. DOI: 10.1182/Blood.V114.22.3774.3774  0.01
2009 Guzman ML, Nasim S, Balys M, Corbett CA, Crooks PA, Jordan CT. Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity. Blood. 114: 3764-3764. DOI: 10.1182/Blood.V114.22.3764.3764  0.01
2009 Ashton JM, Hassane D, Neering S, Bushnell TP, Jordan CT. Synergistically Regulated Genes and Pathways in Leukemias Induced by Co-Expression of BCR-ABL and Nup98-HoxA9. Blood. 114: 3473-3473. DOI: 10.1182/Blood.V114.22.3473.3473  0.01
2009 Rossi RM, Grose V, Pine P, Fisher RI, Jordan CT, Friedberg JW. Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma. Blood. 114: 283-283. DOI: 10.1182/Blood.V114.22.283.283  0.01
2009 Pei S, Guzman ML, Nasim S, Shi L, Crooks PA, Jordan CT. Analysis of the Anti-Leukemia Mechanism of Parthenolide. Blood. 114: 2734-2734. DOI: 10.1182/Blood.V114.22.2734.2734  0.01
2009 Wiedl CM, Horton TM, Rossi RM, Neering SJ, Grose V, Jordan CT. Heterogeneity in Phenotype, Functional Capacity, and Drug Sensitivity for Pediatric Acute Leukemia. Blood. 114: 2654-2654. DOI: 10.1182/Blood.V114.22.2654.2654  0.01
2009 Hassane D, Balys M, Marcucci G, Byrd JC, Jordan CT, Guzman ML. Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML). Blood. 114: 2070-2070. DOI: 10.1182/Blood.V114.22.2070.2070  0.01
2009 Wuensch SA, Rossi RM, Burack R, Rothberg PG, Jordan CT, Young FM. Clonally Related B-NHL Populations and Cell Lines Harbor Subsets with Significant Phenotypic and Functional Heterogeneity. Blood. 114: 1699-1699. DOI: 10.1182/Blood.V114.22.1699.1699  0.01
2009 Guzman ML, Schuurhuis GJ, Jordan CT. Targeting acute myelogenous leukemia stem cells Cancer Stem Cells. 93-108. DOI: 10.1017/CBO9780511605536.007  0.01
2009 Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. ChemInform Abstract: Aminoparthenolides as Novel anti-Leukemic Agents: Discovery of the NF-ϰB Inhibitor, DMAPT (LC-1). Cheminform. 40: no-no. DOI: 10.1002/CHIN.200948181  0.01
2008 Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C, Brennan P, Rowntree C, Pepper C. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8102-11. PMID 19088025 DOI: 10.1158/1078-0432.Ccr-08-1673  0.01
2008 Jordan CT. Can we finally target the leukemic stem cells? Best Practice & Research. Clinical Haematology. 21: 615-20. PMID 19041600 DOI: 10.1016/J.Beha.2008.07.006  0.01
2008 Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood. 112: 4184-92. PMID 18755985 DOI: 10.1182/Blood-2008-02-142190  0.01
2008 Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI, Friedberg JW. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1759-64. PMID 18504251 DOI: 10.1093/Annonc/Mdn365  0.01
2008 Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 622-30. PMID 18489987 DOI: 10.1016/J.Bbmt.2008.02.015  0.01
2008 Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111: 5654-62. PMID 18305216 DOI: 10.1182/Blood-2007-11-126003  0.01
2008 Mao G, Yuan F, Absher K, Jennings CD, Howard DS, Jordan CT, Gu L. Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. Cell Research. 18: 281-9. PMID 18227862 DOI: 10.1038/Cr.2008.14  0.01
2008 Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 111: 4681-9. PMID 18227347 DOI: 10.1182/Blood-2007-11-125278  0.01
2008 Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L, Zhao J. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood. 111: 1644-53. PMID 18025152 DOI: 10.1182/Blood-2007-05-088591  0.01
2008 Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Sen S, Guzman ML, Jordan CT, Hsi ED, Abo A. CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML Blood. 112: 4003-4003. DOI: 10.1182/Blood.V112.11.4003.4003  0.01
2008 Hassane DC, Ashton JM, Guzman ML, Jordan CT. Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans. Blood. 112: 3349-3349. DOI: 10.1182/Blood.V112.11.3349.3349  0.01
2008 Frisch B, Ashton JM, Olm-shipman A, Xing L, Jordan CT, Calvi L. Reciprocal Synergistic Interactions of Leukemic Cells with Osteoclast Progenitors in the Bone Microenvironment Blood. 112: 322-322. DOI: 10.1182/Blood.V112.11.322.322  0.01
2008 Howard D, Liesveld J, Phillips GL, Guzman ML, Jordan CT. A Phase I study using Bortezomib with Weekly Idarubicin for the Treatment of Elderly (>60 YEARS) and Relapsed Patients with Acute Myeloid Leukemia (AML) Blood. 112: 2953-2953. DOI: 10.1182/Blood.V112.11.2953.2953  0.01
2008 Rossi RM, Balys M, Franklin D, Grose V, Fisher RI, Jordan C. Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents. Blood. 112: 1595-1595. DOI: 10.1182/Blood.V112.11.1595.1595  0.01
2007 Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, ... Jordan CT, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 110: 4427-35. PMID 17804695 DOI: 10.1182/Blood-2007-05-090621  0.01
2007 Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 110: 4436-44. PMID 17785584 DOI: 10.1182/Blood-2007-05-088815  0.01
2007 Neering SJ, Bushnell T, Sozer S, Ashton J, Rossi RM, Wang PY, Bell DR, Heinrich D, Bottaro A, Jordan CT. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 110: 2578-85. PMID 17601986 DOI: 10.1182/Blood-2007-02-073031  0.01
2007 Jordan CT. The leukemic stem cell. Best Practice & Research. Clinical Haematology. 20: 13-8. PMID 17336250 DOI: 10.1016/J.Beha.2006.10.005  0.01
2007 Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 27: 600-6. PMID 17204667 DOI: 10.1161/01.Atv.0000257133.60884.44  0.01
2007 Hassane DC, Guzman ML, Corbett C, Li X, Liesveld JL, Young F, Carroll M, Jordan CT. A Search of Public Gene Expression Microarray Data Identifies Novel Agents That Selectively Eradicate AML Stem Cells. Blood. 110: 776-776. DOI: 10.1182/Blood.V110.11.776.776  0.01
2007 Friedberg JW, Kelly J, Voci S, Marquis D, Rich L, Rossi R, Bernstein S, Jordan C, Liesveld J, Fisher RI. Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL). Blood. 110: 2325-2325. DOI: 10.1182/Blood.V110.11.2325.2325  0.01
2007 Frisch BJ, Weber JM, Porter RL, Gigliotti BJ, Smith JN, Olm-Shipman AJ, O’Keefe RJ, Jordan CT, Calvi LM. In Vivo Treatment with Prostaglandin E2 (PGE2) Selectively Expands Short-Term Hematopoietic Stem Cells. Blood. 110: 1254-1254. DOI: 10.1182/Blood.V110.11.1254.1254  0.01
2006 Jordan CT. Searching for leukemia stem cells--not yet the end of the road? Cancer Cell. 10: 253-4. PMID 17045202 DOI: 10.1016/J.Ccr.2006.09.010  0.01
2006 Jordan CT, Guzman ML, Noble M. Cancer stem cells. The New England Journal of Medicine. 355: 1253-61. PMID 16990388 DOI: 10.1056/Nejmra061808  0.01
2006 Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, Jordan CT, Milner LA, Guzman ML, Calvi LM. Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. Bone. 39: 485-93. PMID 16647886 DOI: 10.1016/J.Bone.2006.03.002  0.01
2006 Klebanov L, Jordan C, Yakovlev A. A new type of stochastic dependence revealed in gene expression data. Statistical Applications in Genetics and Molecular Biology. 5: Article7. PMID 16646871 DOI: 10.2202/1544-6115.1189  0.01
2006 Calvi LM, Frisch BJ, Gigliotti BJ, Christianson CA, Weber JM, Jordan CT, O’Keefe RJ. Prostaglandin E2 (PGE2) Regulates Osteoblastic Jagged1 and Expands Primitive Hematopoietic Cells In Vivo. Blood. 108: 89-89. DOI: 10.1182/Blood.V108.11.89.89  0.01
2006 Mullen CA, Campbell A, Young F, Jordan CT. Pre-B Cell Acute Lymphoblastic Leukemia Cells Carrying a Bcr/Abl Translocation Retain Sensitivity to Minor Histocompatibility Antigen Specific T Cells but Are Resistant to Natural Killer Cells: Implications for Manipulation of Graft Versus Leukemia Effects. Blood. 108: 3247-3247. DOI: 10.1182/Blood.V108.11.3247.3247  0.01
2006 Hassane DC, Guzman ML, Li X, Corbett C, Jordan CT. Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death. Blood. 108: 2592-2592. DOI: 10.1182/Blood.V108.11.2592.2592  0.01
2006 Guzman ML, Li X, Corbett C, Rossi RM, Bushnell T, Jordan CT. Rapid Loss of Membrane Integrity and Irreversible Commitment to Cell Death of Primary AML Stem Cells: A Novel Activity for 4-benzyl, 2-methyl,1,2,4-Thiadiazolidine,3,5 Dione (TDZD-8). Blood. 108: 2535-2535. DOI: 10.1182/Blood.V108.11.2535.2535  0.01
2006 Guzman ML, Rossi RM, Li X, Corbett C, Hassane DC, Bushnell T, Carroll M, Sullivan E, Neelakantan S, Crooks PA, Jordan CT. A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells. Blood. 108: 237-237. DOI: 10.1182/Blood.V108.11.237.237  0.01
2006 Jordan CT, Neering SJ, Wang P, Rossi RM, Bushnell T. In Vivo Analyses of Leukemia Stem Cells in Genetically Defined Murine Models of Chronic and Blast Crisis CML. Blood. 108: 236-236. DOI: 10.1182/Blood.V108.11.236.236  0.01
2006 Jordan CT, Guzman ML, Noble M. The authors reply [11] New England Journal of Medicine. 355: 2703.  0.01
2005 Jordan CT. The potential of targeting malignant stem cells as a treatment for leukemia. Future Oncology (London, England). 1: 205-7. PMID 16555992 DOI: 10.1517/14796694.1.2.205  0.01
2005 Jordan CT. Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nature Clinical Practice. Oncology. 2: 224-5. PMID 16264940 DOI: 10.1038/Ncponc0164  0.01
2005 Guzman ML, Jordan CT. Feverfew: weeding out the root of leukaemia. Expert Opinion On Biological Therapy. 5: 1147-52. PMID 16120045 DOI: 10.1517/14712598.5.9.1147  0.01
2005 Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 105: 4163-9. PMID 15687234 DOI: 10.1182/Blood-2004-10-4135  0.01
2005 Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Molecular and Cellular Biology. 25: 1100-12. PMID 15657436 DOI: 10.1128/Mcb.25.3.1100-1112.2005  0.01
2005 Guzman ML, Li X, Corbett C, Hassane DC, Jordan CT. Mechanisms Controlling Selective Death of Leukemia Stem Cells in Response to Parthenolide. Blood. 106: 467-467. DOI: 10.1182/Blood.V106.11.467.467  0.01
2005 Wang P, Young F, Rossi RM, Bushnell T, Jordan CT. Modeling the Origins of Lymphoid Blast Crisis Via Expression of BCR/ABL in Hematopoietic Cells Mutated at the INK4a/ARF Locus. Blood. 106: 464-464. DOI: 10.1182/Blood.V106.11.464.464  0.01
2005 Rossi RM, Henn AD, Conkling R, Guzman ML, Bushnell T, Harvey J, Fisher RI, Jordan CT. The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells. Blood. 106: 1483-1483. DOI: 10.1182/Blood.V106.11.1483.1483  0.01
2005 Nolta JA, Jordan CT. The gold standard improves: A better assay for HSCs Blood. 106: 1141-1142. DOI: 10.1182/Blood-2005-05-2064  0.01
2004 Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 80-97. PMID 15561678 DOI: 10.1182/Asheducation-2004.1.80  0.01
2004 Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Current Opinion in Cell Biology. 16: 708-12. PMID 15530785 DOI: 10.1016/J.Ceb.2004.09.002  0.01
2004 Jordan CT. A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy. Leukemia Research. 28: 1121-2. PMID 15380333 DOI: 10.1016/J.Leukres.2004.05.019  0.01
2004 Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 23: 7178-87. PMID 15378078 DOI: 10.1038/Sj.Onc.1207935  0.01
2004 Liesveld JL, Jordan CT, Phillips GL. The hematopoietic stem cell in myelodysplasia. Stem Cells (Dayton, Ohio). 22: 590-9. PMID 15277704 DOI: 10.1634/Stemcells.22-4-590  0.01
2004 Jordan CT, Saakadze N, Newman JL, Lezhava LJ, Maiers TT, Hillyer WM, Roback JD, Hillyer CD. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion. 44: 1159-65. PMID 15265119 DOI: 10.1111/J.1537-2995.2004.03351.X  0.01
2004 Jordan CT, Roback JD. Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation. Immunologic Research. 29: 209-18. PMID 15181283 DOI: 10.1385/Ir:29:1-3:209  0.01
2004 Goodrum F, Jordan CT, Terhune SS, High K, Shenk T. Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood. 104: 687-95. PMID 15090458 DOI: 10.1182/Blood-2003-12-4344  0.01
2004 Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 11: 97-104. PMID 15024346 DOI: 10.1177/107327480401100216  0.01
2004 Sozer S, Echlin DR, Rossi RM, Grimes BA, Jordan CT. Characterization and Functional Analysis of a Murine Model for Chronic Myeloid Leukemia Stem Cells. Blood. 104: 4476-4476. DOI: 10.1182/Blood.V104.11.4476.4476  0.01
2004 Guzman ML, Karnischky L, Li X, Neering SJ, Rossi RM, Jordan CT. Selective Induction of Apoptosis in Acute Myelogenous Leukemia Stem Cells by the Novel Agent Parthenolide. Blood. 104: 2542-2542. DOI: 10.1182/Blood.V104.11.2542.2542  0.01
2004 Goodrum FD, Jordan CT, Terhune SS, High KP, Shenk T. Human Cytomegalovirus Infection of Primitive Hematopoietic Progenitor Cells: A Model for Latency. Blood. 104: 1703-1703. DOI: 10.1182/Blood.V104.11.1703.1703  0.01
2004 Calvi LM, Weber JM, Guzman ML, Christianson CA, Milner LM, Jordan CT. Osteoblastic Cells and the Hematopoietic Microenvironment: The Notch ligand Jagged1 Is Increased in Osteoblastic Stromal Cells by Parathyroid Hormone (PTH)Treatment. Blood. 104: 1284-1284. DOI: 10.1182/Blood.V104.11.1284.1284  0.01
2004 JORDAN C, DICK J. Abstracts of a Focused Workshop on Malignant Stem Cells in Leukemia and Solid Tumors Cambridge Ontario, Canada, May 7–9, 2004Sponsored by The Leukemia and Lymphoma Society Blood Cells, Molecules, and Diseases. 33: 97-110. DOI: 10.1016/S1079-9796(04)00131-7  0.01
2004 Jordan CT, Dick JE. Abstracts of a Focused Workshop on Malignant Stem Cells in Leukemia and Solid Tumors Cambridge Ontario, Canada, May 7–9, 2004 Blood Cells, Molecules, and Diseases. 33: 97-110. DOI: 10.1016/J.BCMD.2004.05.004  0.01
2003 Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Molecular and Cellular Biology. 23: 8992-9002. PMID 14645512 DOI: 10.1128/Mcb.23.24.8992-9002.2003  0.01
2002 Srour EF, Jordan CT. Isolation and characterization of primitive hematopoietic cells based on their position in the cell cycle. Methods in Molecular Medicine. 63: 93-111. PMID 21437802 DOI: 10.1385/1-59259-140-X:093  0.01
2002 Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proceedings of the National Academy of Sciences of the United States of America. 99: 16255-60. PMID 12456880 DOI: 10.1073/Pnas.252630899  0.01
2002 Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT. Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 16220-5. PMID 12451177 DOI: 10.1073/Pnas.252462599  0.01
2002 Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT, Moscow JA. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Experimental Hematology. 30: 1162-9. PMID 12384147 DOI: 10.1016/S0301-472X(02)00901-3  0.01
2002 Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 16: 559-62. PMID 11960332 DOI: 10.1038/sj.leu.2402446  0.01
2001 Jordan CT, Vanin EF, Marini FC. The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. Current Gene Therapy. 1: 257-65. PMID 12109141 DOI: 10.2174/1566523013348535  0.01
2001 Nolta JA, Jordan CT. Spotlight on hematopoietic stem cells: looking beyond dogma. Introduction. Leukemia. 15: 1677-80. PMID 11681405  0.01
2001 Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 98: 2301-7. PMID 11588023 DOI: 10.1182/Blood.V98.8.2301  0.01
2001 Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 97: 2177-9. PMID 11264190 DOI: 10.1182/Blood.V97.7.2177  0.01
2001 Lemischka IR, Jordan CT. The return of clonal marking sheds new light on human hematopoietic stem cells. Nature Immunology. 2: 11-2. PMID 11135569 DOI: 10.1038/83115  0.01
2000 Evans ME, Jordan CT, Chang SM, Conrad C, Gerberding JL, Kaufman HL, Mayhall CG, Nolta JA, Pilaro AM, Sullivan S, Weber DJ, Wivel NA. Clinical infection control in gene therapy: a multidisciplinary conference. Infection Control and Hospital Epidemiology. 21: 659-73. PMID 11083185 DOI: 10.1086/501711  0.01
2000 Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 14: 1777-84. PMID 11021753 DOI: 10.1038/Sj.Leu.2401903  0.01
1999 Howard DS, Rizzierri DA, Grimes B, Upchurch D, Phillips GL, Stewart AK, Yannelli JR, Jordan CT. Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. Leukemia. 13: 1608-16. PMID 10516763 DOI: 10.1038/Sj.Leu.2401541  0.01
1999 Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP, Farese AM, Whiting-Theobald N, Linton GF, Yamasaki G, Jordan CT, Malech HL. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 94: 2271-86. PMID 10498599 DOI: 10.1182/Blood.V94.7.2271.419K41_2271_2286  0.01
1999 Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proceedings of the National Academy of Sciences of the United States of America. 96: 2988-93. PMID 10077624 DOI: 10.1073/Pnas.96.6.2988  0.01
1998 Jordan CT, Van Zant G. Recent progress in identifying genes regulating hematopoietic stem cell function and fate. Current Opinion in Cell Biology. 10: 716-20. PMID 9914177 DOI: 10.1016/S0955-0674(98)80112-9  0.01
1997 Orlic D, Girard LJ, Anderson SM, Do BK, Seidel NE, Jordan CT, Bodine DM. Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels. Stem Cells (Dayton, Ohio). 15: 23-8; discussion 28-. PMID 9368321 DOI: 10.1002/Stem.5530150805  0.01
1996 Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proceedings of the National Academy of Sciences of the United States of America. 93: 11097-102. PMID 8855315 DOI: 10.1073/Pnas.93.20.11097  0.01
1996 Neering SJ, Hardy SF, Minamoto D, Jordan CT. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors Experimental Hematology. 24: 1057. DOI: 10.1182/Blood.V88.4.1147.Bloodjournal8841147  0.01
1994 Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood. 84: 2422-30. PMID 7919361 DOI: 10.1182/Blood.V84.8.2422.Bloodjournal8482422  0.01
1991 Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proceedings of the National Academy of Sciences of the United States of America. 88: 9026-30. PMID 1717995 DOI: 10.1073/Pnas.88.20.9026  0.01
1991 Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65: 1143-52. PMID 1648448 DOI: 10.1016/0092-8674(91)90010-V  0.01
1990 Jordan CT, McKearn JP, Lemischka IR. Cellular and developmental properties of fetal hematopoietic stem cells. Cell. 61: 953-63. PMID 1972037 DOI: 10.1016/0092-8674(90)90061-I  0.01
1990 Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes & Development. 4: 220-32. PMID 1970972 DOI: 10.1101/Gad.4.2.220  0.01
1988 Greenspan E, Jordan C, Meyskens F, Norton L, Osborne CK, Nixon D, Powles T, Tormey D, Zelen M. Chemoprevention breast cancer workshop, november 20, 1987 panel discussions Cancer Investigation. 6: 663-667. DOI: 10.3109/07357908809082138  0.01
Hide low-probability matches.